GlaxoSmithKline Pakistan Limited (PSX:GLAXO)
Pakistan · Delayed Price · Currency is PKR 354.78
0.00 (0.00%)
At close: May 29, 2026
GlaxoSmithKline Pakistan Cash Flow Statement
Financials in millions PKR. Fiscal year is January - December.
Millions PKR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 10,509 | 10,025 | 6,536 | 533.95 | 2,463 | 5,354 |
Depreciation & Amortization | 1,427 | 1,374 | 1,136 | 932.3 | 859.38 | 775.27 |
Loss (Gain) From Sale of Assets | -82.24 | -74.07 | -21.88 | -82.76 | -124.62 | -633.9 |
Asset Writedown & Restructuring Costs | 42.01 | 42.01 | 18.39 | 6.01 | 18.02 | 15.54 |
Provision & Write-off of Bad Debts | 21.51 | 21.51 | 1.76 | 160.34 | 89.7 | 42.74 |
Other Operating Activities | -1,301 | 180.42 | 1,552 | -703.15 | -431.51 | 1,204 |
Change in Accounts Receivable | -2,592 | -2,279 | 471.58 | 395.71 | -358.67 | -154.15 |
Change in Inventory | -550.23 | -2,739 | -365.39 | -2,256 | -3,363 | -1,077 |
Change in Accounts Payable | 1,371 | 557.26 | -1,009 | 4,332 | 2,827 | -36.69 |
Change in Other Net Operating Assets | 1,376 | 1,555 | -3,257 | -1,386 | -5,142 | -512.05 |
Operating Cash Flow | 10,212 | 8,664 | 5,058 | 1,884 | -3,161 | 4,987 |
Operating Cash Flow Growth | 105.56% | 71.30% | 168.51% | - | - | -16.33% |
Capital Expenditures | -2,455 | -2,583 | -2,775 | -1,649 | -1,533 | -1,304 |
Sale of Property, Plant & Equipment | 257.21 | 275.65 | 134.32 | 212.95 | 244.47 | 777.27 |
Other Investing Activities | 517.66 | 518.14 | 538.91 | 279.45 | 827.1 | 374.94 |
Investing Cash Flow | -1,681 | -1,789 | -2,102 | -1,157 | -461.6 | -151.56 |
Long-Term Debt Repaid | - | -54.31 | -51.12 | -25.59 | -14.6 | -11.46 |
Net Debt Issued (Repaid) | -65.52 | -54.31 | -51.12 | -25.59 | -14.6 | -11.46 |
Common Dividends Paid | -4,743 | -4,742 | -1.76 | -1,845 | -375.03 | -2,062 |
Financing Cash Flow | -4,809 | -4,796 | -52.88 | -1,871 | -389.63 | -2,073 |
Net Cash Flow | 3,722 | 2,079 | 2,903 | -1,144 | -4,012 | 2,762 |
Free Cash Flow | 7,756 | 6,081 | 2,282 | 234.56 | -4,694 | 3,683 |
Free Cash Flow Growth | 206.14% | 166.44% | 873.04% | - | - | -20.69% |
Free Cash Flow Margin | 11.52% | 9.23% | 3.73% | 0.47% | -11.22% | 10.05% |
Free Cash Flow Per Share | 24.35 | 19.09 | 7.17 | 0.74 | -14.74 | 11.57 |
Cash Income Tax Paid | 9,098 | 7,284 | 2,698 | 2,309 | 2,639 | 871.59 |
Levered Free Cash Flow | 8,479 | 6,758 | 3,051 | -1,126 | -1,473 | 3,545 |
Unlevered Free Cash Flow | 8,479 | 6,785 | 3,063 | -1,122 | -1,470 | 3,549 |
Change in Working Capital | -396.1 | -2,906 | -4,160 | 1,085 | -6,036 | -1,780 |